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Association of a Molecular Variant of the
Angiotensinogen Gene and Hypertension
Vasan S. Ramachandran, Daniel Levy, Martin G. Larson, Jose M. Ordovas, Ernst
J. Schaefer, Richard H. Myers, Klaus Lindpaintner, Peter w.F. Wilson. Framingham
Heart Study, Framingham, MA
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A molecular variant of the angiotensinogen gene encoding methionine in-
stead of threonine at position 174 (T174M) has been associated with essen-
tial hypertension (HTN) in case-control studies. We examined the relations of
the T174M allele with HTN in 1401 subjects (707 men, 694 women) from the
Framingham Offspring Study (mean age 50.5, range 25-78 years). Pooled-
and sex-specific simple association analyses revealed no relation between
hypertension status and presence or absence of T174M. Conditional logistic
regression was used to analyze the relations of T174M to HTN in 143 sib-
ships in which at least 1 sibling had HTN. After adjusting for sex and age,
presence of T174M was associated with a nonsignificant increase in proba-
bility of HTN (OR 1.89, 95% CI 0.83-4.29, P = 0.13). Analysis of 25 affected
sibling-pairs with severe HTN suggested an excess sharing of the T174M
allele (p = 0.056).
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gaps. The two populations had similar systolic and diastolic blood pressures,
serum lipid levels and smoking history. Logistic regression analysis including
age in the model indicated that only female gender, beta (an index of arte-
rial stiffness) and the presence of plaque were independently related to the
presence of auscultatory gaps. This study provides the first evidence that
auscultatory gaps are related to the presence of carotid atherosclerosis and
to increased arterial stiffness in hypertensive patients, independently of age.
Although these observations need to be confirmed by prospective studies
they suggest a prognostic relevance of the auscultatory gaps.
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Pre-Donation Post-Donation Change Significance
HRI/min) 68.5 ± 1.5 69.8 ± 1.5 1.4 ± 0.6 p < 0.02
SBP(mmHg) 143.1 ± 2.5 1458 ± 3.1 2.9 ± 2.3 n.s
DBP(mmHg) 732 ± 2.0 75.7 ± 1.7 1.9 ± 1.5 n.s.
PVIJ.!LI 1151 ± 64 954 ± 39 -197 ± 53 p < 0.0001
There were no significant changes in either SBP or DBR The HR increased
significantly, but by only 2.0% (p < 0.02). The PV decreased by 17.1 % (p <
0.0001), which is 8.6 times greater than the percent change in heart rate (p
< 0.01). The PV decrease correlated with the blood loss per kg (r = 0.46, p
< 0.01). We conclude that a significant change in PV occurs with relatively
minor blood loss. Pulse volume analysis may therefore provide an early indi-
cation of hypovolemia due to acute blood loss.
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Borderline Isolated Systolic Hypertension and
Subsequent Risk of Cardiovascular Disease
Christopher J. O'Donnell, Paul M. Ridker, Klaus Berger, Frances LaMotte, Robert
J. Glynn, JoAnn E. Manson, Charles H. Hennekens. Division of Preventive Medicine,
Brigham and Women's Hospital, Boston, MA
1901-801
Mean 195% CII* P < 0.05. ** P< 0.01, STD = ST Segment Depression
ISCHEMIC HEART DISEASE - CHRONIC/SILENT ISCHEMIA
AA = normal. Aa ~ presence of 1T174M allele, aa = presence of 2T174M alleles. Severe
HTN = systolic BP ~ 160 mmHg or diastolic BP ~ 100 mmHg or use of ~2 anti-HTN
medications. Mild HTN ~ systolic BP ~ 140 mmHg or diastolic BP ~ 90 mmHg or use of
a single anti-HTN medication.
Ranolazine Dose Group minus Placebo Group Responses
267 mg tid 400 mg bid 400 mg tid
231 S,38)** 19( 4, 34)* 19 ( 4, 341*
1212,23) 10(-06,20) 10{-01,201
25111,39)** 17( 3. 31)* 22( 8, 361**
1.1% -0.3% 1.9%
A Multicenter Controlled Trial of a Novel
Metabolic Active Compound (Ranolazine) in
Chronic Stable Angina Patients
Conclusions: In this large noninstitutionalized sample, we did not find an
association between the T174M allele and HTN. In a subset of 25 sibships
with severe HTN, however, genetic linkage between the angiotensinogen
locus and severe HTN was suggested.
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Ranolazine significantly increased times to onset of both angina and ST
segment depression at all doses tested. All exercise parameters were sig-
nificantly (P :5 0.01) improved with ranolazine at peak plasma levels com-
pared with placebo as ranolazine plasma levels ranged from 1,350 to 2,130
William B. Smith, Steven Chrysant, William 1. Garland, Thomas S. Parker, Howard
1. Walpole, Ahmad Mokatrin 1, Daniel Gennevois 1, Carl J. Pepine, Syntex
Ranolazine Study Group. University ofFlorida, Gainesville, FL
Ranolazine is a new antianginal agent believed to reduce oxygen demand
through its metabolic action without effects on blood pressure, heart rate
or cardiac function. It was evaluated in a randomized, double-blind, placebo-
controlled, crossover trial with an extended-period Latin square design (5
one week periods). During a placebo phase, 312 patients with chronic stable
angina (:::3 months) receiving multiple antianginals were withdrawn from::: 1
antianginal drugs. After their exercise time had shortened by :::1.0 mins they
were randomized to receive either ranolazine 267 mg tid, 400 mg bid, 400 mg
tid or placebo during each study period. After 1 week of treatment exercise
tolerance (Bruce protocol) and plasma ranolazine levels were measured at
peak (1 hr after dosing) and at trough (8 [tid] or 12 [bid] hr after dosing).
Results at Peak Ranolazjne Blood Level
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Auscultatory Gaps and Target Organ Damage in
Hypertensive Patients
M. Chiara Cavallini, Mary J. Roman, Seymour G. Blank, Riccardo Pini, Thomas
G. Pickering, Richard B. Devereux. The New York Hospital-Cornell University Medical
Center, New York, NY
Guidelines are unclear about treatment of borderline isolated systolic hyper-
tension, defined as both systolic BP 140-159 mmHg and diastolic BP < 90
mmHg. We investigated the association between borderline isolated sys-
tolic hypertension and subsequent risk of myocardial infarction (MI), stroke,
cardiovascular death, and the combined endpoint of important cardiovas-
cular events (nonfatal MI, nonfatal stroke or cardiovascular death) among
22,071 men age 40-84 years followed prospectively for an average of 10.7
years in the Physician's Health Study. Baseline BP and cardiovascular risk fac-
tors were available from completed questionnaires on 16,678 men among
whom 960 subsequently had an incident important cardiovascular event. In
proportional hazards models adjusting for other cardiovascular risk factors,
the relative risks were calculated for those with borderline isolated systolic
hypertension relative to those with both systolic BP < 140 mmHg and dias-
tolic BP < 90 mmHg. These relative risks were 1.05 (95% confidence interval
CI 0.80 to 1.36) for MI, 1.68 (95% CI 1.24 to 2.26) for stroke, 1.61 (95% CI
1.19 to 2.18) for cardiovascular death, and 1.32 (95% CI 1.11 to 1.58) for the
combined endpoint of important cardiovascular events. These associations
were not altered by an analysis excluding participants who reported baseline
treatment for hypertension.
Conclusion: Borderline isolated systolic hypertension is associated with a
significantly increased risk of subsequent important cardiovascular events.
Auscultatory gaps are a common finding in clinical practice but their clinical
and prognostic importance has never been assessed. To examine the rela-
tion of auscultatory gaps to left ventricular and arterial structure and function,
wideband external pulse recordings during cuff deflation to detect ausculta-
tory gaps and ultrasonographic examination of left ventricle and extracranial
carotid artery were performed in 168 unmedicated, asymptomatic hyperten-
sive subjects. Vascular stiffness was also evaluated by simultaneous carotid
pressure waveforms obtained by applanation tonometry of the contralateral
carotid artery. Auscultatory gaps were present in 21 % of the population and
were associated with older age (64 ± 11 vs 55 ± 13 years, p < 0.0005). fe-
male gender (66 vs 44%, p < 0.05) and increased arterial stiffness (beta = 8.5
± 4.6 vs 5.8 ± 3.2, P < 0.005). Differences in arterial stiffness persisted after
controlling for the confounding effects of age and gender. The prevalence of
atherosclerotic plaques was more than two-fold increased among subjects
with gaps (50 vs 22%, p < 0.005). No significant differences were found in
left ventricular structure and function between the subjects with and without
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Procedure TnT < 0.1 0.1-0.2 >0.2
Abdom. Aortic Aneur. 39 (66%) 13 (22%) 7{12%)
Other vascular 160 (79%) 20(10%) 23(11%)
Thoracic 75 (64%) 30 (26%) 12(10%)
Abdominal 99 (89%) 8( 7%) 4( 4%)
Orthopedic 304 (92%) 16( 5%) 12( 4%)
Other 180 (87%) 16( 8%) 10( 5%)
8.1*
4.6
Total
4.3*
1.9
Mortality
Cardiac
38*
27
Lp(a) is a Predictor of Coronary Artery Disease in
Pre-menopausal but not in Post-menopausal
Women
LIPIDS - CLINICAL AND BASIC
Low Total Cholesterol is Associated with Higher
Mortality in Patients with Coronary Heart Disease
Serum Cholesterol and Lipoprotein
Concentrations in Black Bears
1 901-85 1
Low T-C (n ~ 554)
Others (n ~ 13199)
ABSTRACfS 25A
Conclusions: Although data from RHC adds statistically significant infor-
mation to standard clinical and LHC measures, the magnitude is small (12%
of total prognostic information available) and probably does not justify RHC
as routine preoperative investigation.
Elevated serum cholesterol (CHOL) concentration and low HDL concentra-
tion are linked to the development of atherosclerotic heart disease (AHD).
High CHOL levels have been reported in both denning and non-denning
bears, yet coronary artery atherosclerosis has not been observed. Lipopro-
Timothy Floyd, David Garshelis. Ursine Bone Research Laboratory, Hailey, 10;
Minnesota Department of Natural Resources, Grand Rapids, MN
*p < 0.001
Multivariate logistic analysis adjusting for age, gender, past history, clinical
and laboratory findings, yielded a relative risk for total mortality among pts.
with low TC of 1.48 (90% Confidence Interval 1.14-1.93).
Conclusion: In this large group of pts with CAD, low TC was associated
with excess total and cardiac mortality. Longer follow-up and further investi-
gation are necessary to clarify the meaning of this association.
Pts group
Satoshi Sunayarna, Hiroshi Mokuno, Hiroshi Miyano, Hisashi Yokoi. Hiroyuki Daida,
Hiroshi Yamaguchi. Juntendo University, Department of Cardiology, Tokyo, Japan
Coronary artery disease (CAD) risk increases in women after menopause.
Although numerous reports suggest that lipid profile worsening after
menopause may be associated with an increase in CAD among women,
there have been few studies that discussed the contribution of Lp(a). To ex-
amine the association between CAD and Lp(a) in pre-menopausal (PR, <55
yo) and post-menopausal (pO, 0::55 yo) women, we evaluated Lp(a) levels
and other risk factor prevalence in 180 female patients 120 to 77 yo) with an-
giographically defined CAD. Six risk factors were assessed: hyper-Lpla)emia
(Hi-Lp(a), Lpla) 0:: 30 mg/dl). hyper-LDLemia (Hi-LDL, LDL 2: 160 mg/dl), hypo-
HDLemia (Lo-HDL, HDL < 35 mg/dl), hypertension, diabetes, and smoking.
Cases were defined as those who had 2: 1 coronary artery with >50% steno-
sis. There were more patients with Hi-Lp(a) (61 %* vs 27%), Hi-LDL (61 %**
vs 5%) and smoking (61 %** vs 9%) in PR cases (n = 18) as compaved with
those in PR controls (n = 22). PO cases (n ~ 93) had more Lo-HDL (15%*
vs 2%), diabetes (33%** vs 13%) and smokers (61 %** vs 9%) than PO con-
trols (n = 47) did. The median Lp(a) of PR cases was higher than that of PR
controls (38.8*,22.7 mg/dl), and they increased with number of diseased ar-
teries. In contrast, there was no difference in the Lp(a) levels between PO
cases and PO controls 121.7,25.2 mg/dl). Logistic regression model also re-
vealed that Hi-Lp(a) was an independent predictor of CAD after controlling
for Hi-LDL, Lo-HDL. hypertension, diabetes and smoking among PR IB =
2.44, SE = 1.20, P < 0.051. but not among PO. Our data suggests that Lp(a)
may be a strong risk factor for CAD in pre-menopausal women, and in post-
menopausal women other risk factors, such as an estrogen deficiency, may
play an important role. (*p < 0.05, **p < 0.01).
Solomon Behar, Un Goldbourt, Eran Graff, Henrietta Reicher-Reiss,
Valentina Boyko, Michal Benderly, Avi Shotan, Daniel Brunner, BIP Study Group.
Neufeld Cardiac Research Institute, Sheba Medical Center, Tel Hashomer, Israel
Several studies have shown an association between low total cholesterol
(TC) and increased mortality. Among 13,753 patients (pts) of both genders
with coronary artery disease (CAD) aged 45-70 yrs (mean 61 yrs) screened
for the Bezafibrate Infarction Prevention (BIP) Study, 554 pts (4.0%) had low
TC (:::160 mg/dl) mean (147 ± 12 mg/dl). Age, clinical findings and medical
treatments were similarin ptswith 10wTC and pts with TC > 160 mg/dl (mean
222 ± 36 mg/dl). The former had lower mean HDL-C (32.5 ± 8.6 mg/dl) and
triglyceride levels (119 ± 66 mg/dl) in comparison to pts with TC > 160 mg/dl
(37.9 ± 10.0 mg/dl and 164 ± 93 mg/dl respectively) Three year mortality
rates after screening were as follows for both groups:
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83%
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Troponin T and Perioperative Ischemia in
Noncardiac Surgery
Thomas H. Lee, Eric J. Thomas, Paula A. Johnson, Lynn E. Ludwig, David Sacks,
Lee Goldman. Brigham and Women's Hospital and Harvard Medical School, Boston,
MA
Prognostic Value of Right Heart Catheterization
Hemodynamic Data in Surgically Treated Patients
with Coronary Artery Disease
William R. Hathaway, Steven E. McNulty, Karen Pieper, Frank E. Harrell. Jr., Daniel
B. Mark, Robert H. Jones, Thomas M. Bashore, Robert M. Califf, Christopher
M. O'Connor. Duke University Medical Center, Durham, NC
Age yrs (median)
To evaluate troponin T (TnT) as a marker for perioperative ischemia, we
prospectively studied 1028 patients (PTS) undergoing major noncardiac
procedures. Clinical data included preoperative examinations, daily clinical
follow-up, and serial electrocardiograms, CK/CK-MB, and TnT levels. Ma-
jor cardiac complications (CaMPS) were classified by reviewers blinded to
TnT data in 29 (3%) of PTS, inclUding acute myocardial infarction (AMII. pul-
monary edema, cardiac arrest, complete heart block, and sustained ventric-
ular tachycardia or fibrillation. AMI was diagnosed using CK-MB criteria in
14 (1.4%) PTS, for whom peak TnT levels were >0.1 mcg~ in 86% and >0.2
mcg/I in 62%. No postoperative clinical complications occurred to the two
PTS with CK-MB criteria for AMI but normal TnT levels. Among the 1014 PTS
without CK-MB criteria for AMI, CaMPS occurred in 5 (0.6%) of 855 PTS
with TnT S 0.1 mcgll versus 10 (6%) of 159 with higher peak TnT levels (p
< 0.0001). This table shows the distribution of peak TnT levels by procedure
type:
We conclude that Tnt correlates with rates of CaMP after major noncar-
diac surgery even among PTS without AMI by CK-MB criteria. In this cohort,
elevated TnT levels were more common with procedures generally associ-
ated with a higher risk of CaMPS. Long term follow-up is needed to de-
termine whether elevated TnT levels in patients without CaMPS were false
positive results or subclinical ischemic events.
1901-831
Routine right heart catheterization (RHC) provides limited prognostic infor-
mation in medically treated patients with coronary artery disease. The use
of this procedure in patients undergoing coronary artery bypass grafting has
been more widely advocated. To determine the value of this practice, we
investigated the added prognostic content of hemodynamic data obtained
from 11 RHC variables in 1054 consecutive surgically treated patients (pts)
with significant coronary artery disease (0::75% stenosis) between 8/6/69 and
1/1/80. During this period, RHC was performed routinely on all patients un-
dergoing left heart catheterization (LHC). Follow up was 97% complete. Uni-
variate RHC predictors of survival included pulmonary vascular resistance
(PVR). right atrial mean (RAMI. CO, CI, AV02 difference, RV systolic pressure,
PA systolic, mean and diastolic pressures, and pulmonary capillary wedge
pressure (p < 0.0001 for each).
ng base/mL. No significant differences between ranolazine and placebo were
observed at trough with mean ranolazine plasma levels ranging from 235 to
514 ng base/mL. No clinically meaningful hemodynamic changes or adverse
events occurred with ranolazine compared with placebo. In summary, ra-
nolazine was well tolerated over a wide range of plasma levels. Ranolazine
increased exercise times with no detectable effect on cardiac hemodynam-
ics in patients with chronic stable angina taking other antianginal drugs.
Male
EF (median)
Hx of CHF
PriorMI
LVEDP (median)
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Using a Cox model the independent predictive value of each RHC vari-
able was analyzed when added to a prognostic model derived from clini-
cal and LHC data. RAM (x 2 = 18.5, P < 0.001) and PVR (x 2 = 8.45, P <
0.001) added independent information to the standard clinical and invasive
(left heart) prognostic factors. A significant interaction was found between
PVR and EF Ip = 0.0067) indicating that elevated PVR contained more prog-
nostic information in patients with normal or elevated EF.
